Liftstream is an executive search recruitment company in the life sciences sector
Roche announces acquisition of InterMune
Authored by James Sheppard
Posted in Uncategorized
Tagged acquisition, Bay Area Cluster, bioValley, Boston Biotech, Genentech, IDF, idiopathic pulmonary fibrosis, InterMune, M&A, pirfenidone, Roche, Severin Schwan, Switzerland
Leave a comment
Roche purchases diagnostic company IQuum
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, acquisition, Asia Pac, bioValley, Boston Biotech, Chief Operation Officer, IQuum, IVD, Latin America, Liat Analyzer, Liat Influenza, M&A, PoC, Point of Care Diagnostics, Roche, Roche Diagnostics, Roland Diggelmann
Leave a comment
Covagen raises $63m for targeted antibody work
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged ANTI TNF/IL-17A, antibody, Ascent Biomedical Ventures, Avi Kometz, bispecific, COVA322, Covagen, Dr Dragan Grabulovski, Dr Julian Bertschinger, Dr Karl Naegler, Edmond de Rothschild], Elias Papatheodorou, ETH Zurich, Fynomers, Gimv, Investment, Medigene, Merck Serono, Micromet, Mitsubishi Tanabe Pharma Corporation, MP Healthcare Venture Management, Novartis Venture Fund, Prof Christoph Lengauer, Roche, Seroba Kernel Life Sciences, Sir Greg Winter, Third Rock Ventures, trispecific, Ventech, venture capital
Leave a comment
Symphogen’s Monoclonal Antibody Technology Making Waves
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, antibody drug conjugate, clinical trials, conjugated mAb, epidermal growth factor receptor, Essex Woodland, European Society of Hematology, Genentech, hematology, Kirsten Drejer, Medicon Valley, Merck, monoclonal antibody, Novo A/S, oncology, Phase II, PKA, Roche, squamous cell carcinoma of the head & neck, SYM004, Symphogen
Leave a comment
Roche Returns to Antibiotics with Polyphor Deal
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged A*STAR, antibiotics, AstraZeneca, bacterial infection, CDC, Center for Disease Control & Prevention, clinical development, ETC and ETPL, gRED, Head of Infectious Diseases Discovery and Translational, hospital-acquired infection, infection, Infectious Disease, John Reed, macrocycle, partnering, Polyphor, pRED, Pseudomonas aeruginosa, Roche, Singapore, Switzerland, Tom Frieden
Leave a comment
Pacific Biosciences rockets after Roche Deal
Authored by James Sheppard
Posted in Medical Device, Pharmaceutical business
Tagged 3rd generation sequencing, Bay Area Cluster, Dan Zabrowski, diagnostics, illumina, in-vitro diagnostics, IVDs, Mike Hunkapiller, PacBio, Pacific Bioscience, Roche, Roche Applied Science, Roche Diagnostics, Roche Molecular Systems, sequencing technology, SMRT
Leave a comment
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Aegerion, Alexion, Amgen, BioMarin, Bloomberg, Breakthrough Therapy, Catalyst Pharmaceutical Partners, Chiesi, Chiesi Farmaceutici, EMA, FDA, Flemming Ornskov, Human Genetic Therapies, Jean-Jacques Bienaimé, Kamada, Kyprolis, life sciences, lysosomal storage diseases, M&A, Nexavar, NPS Pharmaceuticals, Onyx, Orphan drugs, pharmaceutical industry, rare diseases, regenerative medicine, Roche, San Francisco, Sarepta, Shire, speciality pharma, Ugo di Francesco, uniQure, Zymenex
Leave a comment
Roche scores conditional European win with Erivedge
Authored by Karl Simpson
Posted in Pharmaceutical business
Tagged antibody, ASCO, basal cell carcinoma, BCC, BMS, CHMP, Conditional approval, conditional marketing authorization, CUDC-907, Curis Inc, EMA, Erivedge, europe, European Commission, Genentech, HDAC inhibitor, IAP proteins, immunotherapy, Melanoma, Merck, MPDL3280A, oncolgy, PD-1, PI3K, Roche, vismodegib
Leave a comment
Roche reaffirms commitment to Hematology Testing
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged anaemia, Bausch & Lomb, blood diseases, Bloodhound, Boston, Boston Biotech cluster, CMI, Constitution Medical Inc, COO, diagnostics, hematology, laboratory solutions, leukaemia, Roche, Roche Diagnostics, Roland Diggelmann, Valeant, Warburg Pincus
Leave a comment